FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892347132> ?p ?o ?g. }

• W2892347132 endingPage "3039" @default.
• W2892347132 startingPage "3031" @default.
• W2892347132 abstract "Purpose Cetuximab in combination with chemotherapy is a standard-of-care first-line treatment regimen for patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC); however, the efficacy of cetuximab plus leucovorin, fluorouracil, and oxaliplatin (FOLFOX) has never before been proven in a controlled and randomized phase III trial. To our knowledge, the TAILOR trial ( ClinicalTrials.gov identifier: NCT01228734) is the first randomized, multicenter, phase III study of the addition of cetuximab to first-line FOLFOX prospectively choosing a RAS wt population and thus providing confirmative data for the efficacy and safety of cetuximab plus FOLFOX versus FOLFOX alone. Patients and Methods TAILOR is an open-label, randomized (1:1), multicenter, phase III trial in patients from China comparing FOLFOX-4 with or without cetuximab in RAS wt ( KRAS/ NRAS, exons 2 to 4) mCRC. The primary end point of TAILOR was progression-free survival time; secondary end points included overall survival time, overall response rate, and safety and tolerability. Results In the modified intent-to-treat population of 393 patients with RAS wt mCRC, adding cetuximab to FOLFOX-4 significantly improved the primary end point of progression-free survival time compared with FOLFOX-4 alone (hazard ratio, 0.69; 95% CI, 0.54 to 0.89; P = .004; median, 9.2 v 7.4 months, respectively), as well as the secondary end points of overall survival time (current assessment after 300 events: hazard ratio, 0.76; 95% CI, 0.61 to 0.96; P = .02; median, 20.7 v 17.8 months, respectively) and overall response rate (odds ratio, 2.41; 95% CI, 1.61 to 3.61; P < .001; 61.1% v 39.5%, respectively). Treatment was well tolerated, and there were no new or unexpected safety findings. Conclusion The TAILOR study met all of its objectives and relevant clinical end points, confirming cetuximab in combination with FOLFOX as an effective standard-of-care first-line treatment regimen for patients with RAS wt mCRC." @default.
• W2892347132 created "2018-09-27" @default.
• W2892347132 creator A5000432967 @default.
• W2892347132 creator A5004116400 @default.
• W2892347132 creator A5005260055 @default.
• W2892347132 creator A5005706767 @default.
• W2892347132 creator A5011894634 @default.
• W2892347132 creator A5012492614 @default.
• W2892347132 creator A5012852394 @default.
• W2892347132 creator A5013628889 @default.
• W2892347132 creator A5016456840 @default.
• W2892347132 creator A5025294420 @default.
• W2892347132 creator A5027922054 @default.
• W2892347132 creator A5029636776 @default.
• W2892347132 creator A5037920295 @default.
• W2892347132 creator A5040769857 @default.
• W2892347132 creator A5043672686 @default.
• W2892347132 creator A5044447392 @default.
• W2892347132 creator A5045553246 @default.
• W2892347132 creator A5051014138 @default.
• W2892347132 creator A5055723755 @default.
• W2892347132 creator A5057704753 @default.
• W2892347132 creator A5062179244 @default.
• W2892347132 creator A5068044246 @default.
• W2892347132 creator A5070745750 @default.
• W2892347132 creator A5071654004 @default.
• W2892347132 creator A5071672663 @default.
• W2892347132 creator A5078534545 @default.
• W2892347132 creator A5087661837 @default.
• W2892347132 date "2018-10-20" @default.
• W2892347132 modified "2023-10-18" @default.
• W2892347132 title "Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial" @default.
• W2892347132 cites W1727309928 @default.
• W2892347132 cites W1799482054 @default.
• W2892347132 cites W1968282664 @default.
• W2892347132 cites W1985199765 @default.
• W2892347132 cites W2005348280 @default.
• W2892347132 cites W2015132197 @default.
• W2892347132 cites W2020830322 @default.
• W2892347132 cites W2036045525 @default.
• W2892347132 cites W2037142137 @default.
• W2892347132 cites W2061677297 @default.
• W2892347132 cites W2085633477 @default.
• W2892347132 cites W2095201384 @default.
• W2892347132 cites W2112570485 @default.
• W2892347132 cites W2125877119 @default.
• W2892347132 cites W2125955619 @default.
• W2892347132 cites W2129255527 @default.
• W2892347132 cites W2131183275 @default.
• W2892347132 cites W2134142320 @default.
• W2892347132 cites W2139168548 @default.
• W2892347132 cites W2142564546 @default.
• W2892347132 cites W2144425748 @default.
• W2892347132 cites W2145070131 @default.
• W2892347132 cites W2158863975 @default.
• W2892347132 cites W2271299200 @default.
• W2892347132 cites W2470575266 @default.
• W2892347132 cites W2512571828 @default.
• W2892347132 cites W2520338075 @default.
• W2892347132 cites W2531319683 @default.
• W2892347132 cites W2558788971 @default.
• W2892347132 cites W2609927476 @default.
• W2892347132 cites W2754611328 @default.
• W2892347132 cites W4250745281 @default.
• W2892347132 doi "https://doi.org/10.1200/jco.2018.78.3183" @default.
• W2892347132 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6324088" @default.
• W2892347132 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30199311" @default.
• W2892347132 hasPublicationYear "2018" @default.
• W2892347132 type Work @default.
• W2892347132 sameAs 2892347132 @default.
• W2892347132 citedByCount "134" @default.
• W2892347132 countsByYear W28923471322018 @default.
• W2892347132 countsByYear W28923471322019 @default.
• W2892347132 countsByYear W28923471322020 @default.
• W2892347132 countsByYear W28923471322021 @default.
• W2892347132 countsByYear W28923471322022 @default.
• W2892347132 countsByYear W28923471322023 @default.
• W2892347132 crossrefType "journal-article" @default.
• W2892347132 hasAuthorship W2892347132A5000432967 @default.
• W2892347132 hasAuthorship W2892347132A5004116400 @default.
• W2892347132 hasAuthorship W2892347132A5005260055 @default.
• W2892347132 hasAuthorship W2892347132A5005706767 @default.
• W2892347132 hasAuthorship W2892347132A5011894634 @default.
• W2892347132 hasAuthorship W2892347132A5012492614 @default.
• W2892347132 hasAuthorship W2892347132A5012852394 @default.
• W2892347132 hasAuthorship W2892347132A5013628889 @default.
• W2892347132 hasAuthorship W2892347132A5016456840 @default.
• W2892347132 hasAuthorship W2892347132A5025294420 @default.
• W2892347132 hasAuthorship W2892347132A5027922054 @default.
• W2892347132 hasAuthorship W2892347132A5029636776 @default.
• W2892347132 hasAuthorship W2892347132A5037920295 @default.
• W2892347132 hasAuthorship W2892347132A5040769857 @default.
• W2892347132 hasAuthorship W2892347132A5043672686 @default.
• W2892347132 hasAuthorship W2892347132A5044447392 @default.
• W2892347132 hasAuthorship W2892347132A5045553246 @default.
• W2892347132 hasAuthorship W2892347132A5051014138 @default.
• W2892347132 hasAuthorship W2892347132A5055723755 @default.
• W2892347132 hasAuthorship W2892347132A5057704753 @default.

• next